Efficacy of intravitreal Bevacizumab for state 3+ retinopathy of prematurity.

The authors, representatives of the "BEAT-ROP Cooperative Group," showed that intravitreal bevacizumab monoclonal antibody therapy in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone one disease compared to conventional laser therapy, and led to a recurrence rate of 6% versus 42% with conventional laser therapy. Digital facsimile from New Engl. J. Med. at this link.

Order of authorship in the original publication: Mintz-Hintner, Kennedy, Chuang.

(Thanks to Juan Weiss for this reference and its interpretation.)